- Email: [email protected]
Bupropion for the treatment of nicotine dependence
October 2004, Vol 126, No. 4_MeetingAbstracts Abstract: Poster Presentations | October 2004
Bupropion for the treatment of nicotine dependence Michalis G. Patentalakis, MD; Emmanuil Kastanakis, MD; Maria Dimitriadou; Moshakis Moshos, MD; Elias G. Karabatsos, MD*; Antony E. Kopanakis, MD Naxos Hospital, Naxos, Greece Chest Chest. 2004;126(4_MeetingAbstracts):866S. doi:10.1378/chest.126.4_MeetingAbstracts.866S-a
Abstract PURPOSE: The aim of the study was to estimate the smoking cessation success rates of bupropion sustained release (SR) as medical treatment given daily for 8 weeks. METHODS: 368 individuals with mean age the 46 years (range 22 to 66 years), who smoked 10 or more cigarettes per day, had high nicotine dependence and without clinical depression, participated in this study, which took place in the special medical center of smoking cessation of a hospital in Greece. A total of 245 participants received bupropion SR 150 mg daily for 1 week and then 300 mg daily for 7 weeks (total duration of medication 8 weeks) in combination with counseling. The rest 123 were treated with advisory support. The target quitting date was one week after the beginning of treatment. Brief counseling has been provided by telephone contacts the first week of the therapy and then every 2 weeks for 3 months treatment, while the result has been recorded. Clinical visits were scheduled after 2 weeks, 2nd, 6th, and 12th month of treatment. RESULTS: 179 (73%) individuals completed the medical treatment. The treatment has been interrupted by 27 (11.1%) individuals due to unserious side effects (Xerostomia, insomnia, anxiety, nausea) and by 39 (15.9%) due to unwillingness. 66 individuals from 179 (37%) interrupted smoking after 2 months, 59 (33%) after 3 months and 52 (29%) after 6 months treatment. Among 123 who received only advisory support, interrupted smoking 19 (15.5%) after 2 months, 16 (13%) after 3 months and 15 (12.2%) after 6 months treatment. CONCLUSION: Treatment with bupropion SR in combination with counseling resulted in significantly higher long-term rates of smoking cessation than use only advisory support. We observed a moderate to high percentence of side effects, which are unserious and temporary. CLINICAL IMPLICATIONS: Smoking cessation is associated with clear health benefits and therefore should always be a major health care goal. Behavioral and pharmacologic methods help patients stop smoking. DISCLOSURE: E.G. Karabatsos, None. Wednesday, October 27, 2004 12:30 PM- 2:00 PM
Bupropion for the treatment of nicotine dependence Michalis G. Patentalakis, MD; Emmanuil Kastanakis, MD; Maria Dimitriadou; Moshakis Moshos, MD; Elias G. Karabatsos, MD*; Antony E. Kopanakis, MD Naxos Hospital, Naxos, Greece Chest Chest. 2004;126(4_MeetingAbstracts):866S. doi:10.1378/chest.126.4_MeetingAbstracts.866S-a
Abstract PURPOSE: The aim of the study was to estimate the smoking cessation success rates of bupropion sustained release (SR) as medical treatment given daily for 8 weeks. METHODS: 368 individuals with mean age the 46 years (range 22 to 66 years), who smoked 10 or more cigarettes per day, had high nicotine dependence and without clinical depression, participated in this study, which took place in the special medical center of smoking cessation of a hospital in Greece. A total of 245 participants received bupropion SR 150 mg daily for 1 week and then 300 mg daily for 7 weeks (total duration of medication 8 weeks) in combination with counseling. The rest 123 were treated with advisory support. The target quitting date was one week after the beginning of treatment. Brief counseling has been provided by telephone contacts the first week of the therapy and then every 2 weeks for 3 months treatment, while the result has been recorded. Clinical visits were scheduled after 2 weeks, 2nd, 6th, and 12th month of treatment. RESULTS: 179 (73%) individuals completed the medical treatment. The treatment has been interrupted by 27 (11.1%) individuals due to unserious side effects (Xerostomia, insomnia, anxiety, nausea) and by 39 (15.9%) due to unwillingness. 66 individuals from 179 (37%) interrupted smoking after 2 months, 59 (33%) after 3 months and 52 (29%) after 6 months treatment. Among 123 who received only advisory support, interrupted smoking 19 (15.5%) after 2 months, 16 (13%) after 3 months and 15 (12.2%) after 6 months treatment. CONCLUSION: Treatment with bupropion SR in combination with counseling resulted in significantly higher long-term rates of smoking cessation than use only advisory support. We observed a moderate to high percentence of side effects, which are unserious and temporary. CLINICAL IMPLICATIONS: Smoking cessation is associated with clear health benefits and therefore should always be a major health care goal. Behavioral and pharmacologic methods help patients stop smoking. DISCLOSURE: E.G. Karabatsos, None. Wednesday, October 27, 2004 12:30 PM- 2:00 PM